<DOC>
	<DOCNO>NCT00447772</DOCNO>
	<brief_summary>The aim demonstrate equivalent efficacy safety treatment two frequent form cervical dystonia ( predominantly rotational torticollis predominantly laterocollis ) standard initial dose 500 unit Dysport® . The patient assign one two basic type cervical dystonia , either predominantly rotational torticollis predominantly laterocollis basis clinical examination . This determine therapy administer , use clearly define , structure injection protocol .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Dysport® Cervical Dystonia</brief_title>
	<detailed_description />
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<mesh_term>Torticollis</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>De novo patient cervical dystonia Outpatient Patients age 18 year old Written inform consent participate study Pretreatment cervical dystonia botulinum toxin Pretreatment botulinum toxin indication cervical dystonia within past 12 month Pure retro antecollis Neurological disease may affect head neck motor function neuromuscular transmission , e.g . polyneuropathy pareses , myasthenia , myopathy , motor neurone disease , Bekhterev 's disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Dysport , Cervical Dystonia</keyword>
</DOC>